SGMT SAGIMET BIOSCIENCES INC revenue, earnings and financials
For the quarter ended June 30, 2026, SAGIMET BIOSCIENCES INC reported revenue of n/a, net income of −$14.0M and diluted EPS of −$0.26; for the fiscal year ended December 2025 revenue was n/a.
SGMT annual revenue and earnings
- Fiscal year ended Dec 2025: revenue n/a, gross profit n/a, operating income −$56.9M, net income −$51.0M (margin n/a), EPS −$1.58
- Fiscal year ended Dec 2024: revenue n/a, gross profit n/a, operating income −$54.5M, net income −$45.6M (margin n/a), EPS −$1.45
- Fiscal year ended Dec 2023: revenue $2.00M, gross profit n/a, operating income −$30.7M, net income −$27.9M (margin -1393.8%), EPS −$2.66
- Fiscal year ended Dec 2022: revenue n/a, gross profit n/a, operating income −$31.1M, net income −$30.5M (margin n/a), EPS −$165.20
SGMT quarterly revenue and earnings
- Quarter ended Jun 30, 2026: revenue n/a, net income −$14.0M, EPS −$0.26
- Quarter ended Mar 31, 2026: revenue n/a, net income −$10.7M, EPS −$0.33
- Quarter ended Dec 31, 2025 (from the annual report): revenue n/a, net income −$9.57M, EPS −$0.30
- Quarter ended Sep 30, 2025: revenue n/a, net income −$12.9M, EPS −$0.40
- Quarter ended Jun 30, 2025: revenue n/a, net income −$10.4M, EPS −$0.32
- Quarter ended Mar 31, 2025: revenue n/a, net income −$18.2M, EPS −$0.56
- Quarter ended Dec 31, 2024 (from the annual report): revenue n/a, net income −$16.2M, EPS −$0.52
- Quarter ended Sep 30, 2024: revenue n/a, net income −$14.6M, EPS −$0.45
- Quarter ended Jun 30, 2024: revenue n/a, net income −$8.12M, EPS −$0.25
- Quarter ended Mar 31, 2024: revenue n/a, net income −$6.63M, EPS −$0.23
- Quarter ended Dec 31, 2023 (from the annual report): revenue n/a, net income −$8.15M, EPS $69.07
- Quarter ended Sep 30, 2023: revenue $2.00M, net income −$6.35M, EPS −$0.35
- Quarter ended Jun 30, 2023: revenue n/a, net income −$6.79M, EPS −$35.80
- Quarter ended Mar 31, 2023: revenue n/a, net income −$6.59M, EPS −$35.58
- Quarter ended Dec 31, 2022 (from the annual report): revenue n/a, net income −$7.20M, EPS n/a
- Quarter ended Sep 30, 2022: revenue n/a, net income −$7.47M, EPS −$40.34
- Quarter ended Jun 30, 2022: revenue n/a, net income −$7.10M, EPS −$38.37
- Quarter ended Mar 31, 2022: revenue n/a, net income −$8.74M, EPS n/a
SGMT cash flow, buybacks and dividends
- Fiscal year ended Dec 2025: operating cash flow −$45.7M, share buybacks n/a
- Fiscal year ended Dec 2024: operating cash flow −$42.4M, share buybacks n/a
- Fiscal year ended Dec 2023: operating cash flow −$23.8M, share buybacks n/a
- Fiscal year ended Dec 2022: operating cash flow −$24.5M, share buybacks n/a
SGMT balance sheet
- Jun 30, 2026: cash $166M, total assets $263M, total liabilities $7.28M, shareholders' equity $256M
- Mar 31, 2026: cash $36.6M, total assets $108M, total liabilities n/a, shareholders' equity $102M
- Dec 31, 2025: cash $35.0M, total assets $116M, total liabilities $5.10M, shareholders' equity $111M
- Sep 30, 2025: cash $32.5M, total assets $128M, total liabilities n/a, shareholders' equity $119M
- Jun 30, 2025: cash $42.3M, total assets $137M, total liabilities n/a, shareholders' equity $130M
- Mar 31, 2025: cash $64.7M, total assets $146M, total liabilities $7.18M, shareholders' equity $139M
- Dec 31, 2024: cash $75.8M, total assets $160M, total liabilities $4.45M, shareholders' equity $156M
- Sep 30, 2024: cash $77.0M, total assets $175M, total liabilities $4.09M, shareholders' equity $171M
Is SGMT profitable?
No. SAGIMET BIOSCIENCES INC lost $47.1M over the last four quarters.
What is SGMT's EPS?
Diluted earnings per share over the last four quarters were −$1.29; −$0.26 in the latest quarter.